211 related articles for article (PubMed ID: 34727492)
1. A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer.
Kim HR; Lee SJ; Park S; Jung HA; Lee SH; Jeong HS; Chung MK; Ahn MJ
Cancer Res Treat; 2022 Jul; 54(3):719-727. PubMed ID: 34727492
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).
Kim Y; Lee SJ; Lee JY; Lee SH; Sun JM; Park K; An HJ; Cho JY; Kang EJ; Lee HY; Kim J; Keam B; Kim HR; Lee KE; Choi MY; Lee KH; Ahn MJ
Cancer; 2017 Jun; 123(11):1958-1964. PubMed ID: 28102887
[TBL] [Abstract][Full Text] [Related]
3. Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies.
Airoldi M; Pedani F; Succo G; Gabriele AM; Ragona R; Marchionatti S; Bumma C
Cancer; 2001 Feb; 91(3):541-7. PubMed ID: 11169936
[TBL] [Abstract][Full Text] [Related]
4. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
[TBL] [Abstract][Full Text] [Related]
5. A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer.
Rodriguez CP; Wu QV; Voutsinas J; Fromm JR; Jiang X; Pillarisetty VG; Lee SM; Santana-Davila R; Goulart B; Baik CS; Chow LQM; Eaton K; Martins R
Clin Cancer Res; 2020 Feb; 26(4):837-845. PubMed ID: 31796519
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J; Aupérin A; Fayette J; Saada-Bouzid E; Lafond C; Taberna M; Geoffrois L; Martin L; Capitain O; Cupissol D; Castanie H; Vansteene D; Schafhausen P; Johnson A; Even C; Sire C; Duplomb S; Evrard C; Delord JP; Laguerre B; Zanetta S; Chevassus-Clément C; Fraslin A; Louat F; Sinigaglia L; Keilholz U; Bourhis J; Mesia R; ; ;
Lancet Oncol; 2021 Apr; 22(4):463-475. PubMed ID: 33684370
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy with taxane and platinum in patients with salivary gland carcinoma: a retrospective study of docetaxel plus cisplatin and paclitaxel plus carboplatin.
Onaga R; Enokida T; Ito K; Ueda Y; Okano S; Fujisawa T; Wada A; Sato M; Tanaka H; Takeshita N; Tanaka N; Hoshi Y; Tahara M
Front Oncol; 2023; 13():1185198. PubMed ID: 37397398
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Matsumura S; Iwahashi M; Yamaue H
Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 26725778
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.
Wong SJ; Karrison T; Hayes DN; Kies MS; Cullen KJ; Tanvetyanon T; Argiris A; Takebe N; Lim D; Saba NF; Worden FP; Gilbert J; Lenz HJ; Razak AR; Roberts JD; Vokes EE; Cohen EE
Ann Oncol; 2016 Feb; 27(2):318-23. PubMed ID: 26598548
[TBL] [Abstract][Full Text] [Related]
10. Salivary gland carcinoma treated with concomitant chemoradiation with intraarterial cisplatin and docetaxel.
Maruya S; Namba A; Matsubara A; Kakehata S; Takeda I; Shirasaki T; Hatayama Y; Nagahata M; Yokoyama J; Shinkawa H
Int J Clin Oncol; 2006 Oct; 11(5):403-6. PubMed ID: 17058139
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck.
Hong MH; Kim CG; Koh YW; Choi EC; Kim J; Yoon SO; Kim HR; Cho BC
Head Neck; 2018 Jan; 40(1):55-62. PubMed ID: 29044862
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Kim MJ; Kim SM; Jung HA; Hong JY; Chang WJ; Choi MK; Kim HS; Sun JM; Park K; Ahn MJ
Korean J Intern Med; 2019 Sep; 34(5):1107-1115. PubMed ID: 29914230
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
Schöffski P; Catimel G; Planting AS; Droz JP; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske AR
Ann Oncol; 1999 Jan; 10(1):119-22. PubMed ID: 10076732
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma.
Ghosal N; Mais K; Shenjere P; Julyan P; Hastings D; Ward T; Ryder WD; Bruce I; Homer J; Slevin NJ
Br J Oral Maxillofac Surg; 2011 Oct; 49(7):510-5. PubMed ID: 21071117
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck.
Specht L; Larsen SK; Hansen HS
Ann Oncol; 2000 Jul; 11(7):845-9. PubMed ID: 10997812
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study.
Guigay J; Fayette J; Dillies AF; Sire C; Kerger JN; Tennevet I; Machiels JP; Zanetta S; Pointreau Y; Bozec Le Moal L; Henry S; Schilf A; Bourhis J
Ann Oncol; 2015 Sep; 26(9):1941-1947. PubMed ID: 26109631
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma.
Hill ME; Constenla DO; A'Hern RP; Henk JM; Rhys-Evans P; Breach N; Archer D; Gore ME
Oral Oncol; 1997 Jul; 33(4):275-8. PubMed ID: 9307718
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
Locati LD; Perrone F; Cortelazzi B; Bergamini C; Bossi P; Civelli E; Morosi C; Lo Vullo S; Imbimbo M; Quattrone P; Dagrada GP; Granata R; Resteghini C; Mirabile A; Alfieri S; Orlandi E; Mariani L; Saibene G; Pilotti S; Licitra L
Eur J Cancer; 2016 Dec; 69():158-165. PubMed ID: 27821319
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic gastric cancer.
Park KW; Ahn JS; Park YS; Lee J; Kang JH; Park JO; Lim HY; Im YH; Kang WK; Park K; Lee SI
Cancer Chemother Pharmacol; 2007 Jan; 59(1):17-21. PubMed ID: 16721549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
